Hamel Associates, Inc. Novartis Ag Transaction History
Hamel Associates, Inc.
- $324 Million
- Q3 2024
A detailed history of Hamel Associates, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Hamel Associates, Inc. holds 8,680 shares of NVS stock, worth $854,546. This represents 0.31% of its overall portfolio holdings.
Number of Shares
8,680
Previous 8,645
0.4%
Holding current value
$854,546
Previous $920,000
8.48%
% of portfolio
0.31%
Previous 0.29%
Shares
24 transactions
Others Institutions Holding NVS
# of Institutions
1,437Shares Held
131MCall Options Held
1.12MPut Options Held
1.83M-
Dodge & Cox San Francisco, CA12.2MShares$1.2 Billion0.85% of portfolio
-
Primecap Management CO Pasadena, CA12MShares$1.18 Billion1.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.09MShares$797 Million0.23% of portfolio
-
Morgan Stanley New York, NY6.98MShares$688 Million0.06% of portfolio
-
Loomis Sayles & CO L P5.77MShares$568 Million0.87% of portfolio
About NOVARTIS AG
- Ticker NVS
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,151,000,064
- Market Cap $212B
- Description
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...